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Nearly one-third of individuals with 22q11.2 deletion syn-
drome (22q11.2DS) develop a psychotic disorder during 
life, most of them by early adulthood. Importantly, a full-
blown psychotic episode is usually preceded by subthresh-
old symptoms. In the current study, 760 participants (aged 
6–55 years) with a confirmed hemizygous 22q11.2 microde-
letion have been recruited through 10 medical sites world-
wide, as part of an international research consortium. Of 
them, 692 were nonpsychotic and with complete measure-
ment data. Subthreshold psychotic symptoms were assessed 
using the Structured Interview for Prodromal Syndromes 
(SIPS). Nearly one-third of participants met criteria for 
positive subthreshold psychotic symptoms (32.8%), less 
than 1% qualified for acute positive subthreshold symp-
toms, and almost a quarter met criteria for negative/disor-
ganized subthreshold symptoms (21.7%). Adolescents and 
young adults (13–25 years) showed the highest rates of sub-
threshold psychotic symptoms. Additionally, higher rates 
of anxiety disorders and attention deficit/hyperactivity dis-
order (ADHD) were found among the study participants 
with subthreshold psychotic symptoms compared to those 
without. Full-scale IQ, verbal IQ, and global functioning 
(GAF) scores were negatively associated with participants’ 
subthreshold psychotic symptoms. This study represents 
the most comprehensive analysis reported to date on sub-
threshold psychosis in 22q11.2DS. Novel findings include 
age-related changes in subthreshold psychotic symptoms 
and evidence that cognitive deficits are associated with sub-
threshold psychosis in this population. Future studies should 
longitudinally follow these symptoms to detect whether and 
how early identification and treatment of these manifesta-
tions can improve long-term outcomes in those that eventu-
ally develop a psychotic disorder.
Key words:  velocardiofacial syndrome/subthreshold 
psychotic symptoms/structured interview for 
prodromal syndromes/anxiety disorder/global 
assessment of  functioning (GAF)/attention deficit/
hyperactivity disorder (ADHD)/IQ/DiGeorge 
syndrome
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Introduction
22q11.2 deletion syndrome (22q11.2DS) is a genetic disor-
der that occurs in about 1 in 4000 live births.1 Psychiatric 
comorbidities are highly prevalent in 22q11.2DS, affect-
ing three-quarters of all diagnosed individuals.2 Notable 
among these are Schizophrenia-spectrum disorders; about 
a third of 22q11.2DS individuals develop a psychotic dis-
order during life, most of them by early adulthood.3 Thus, 
a diagnosis of 22q11.2DS constitutes a 30-fold increased 
risk of developing psychosis over the general population 
and a 10-fold elevated risk over other populations with 
neurodevelopmental disabilities.4 Therefore, 22q11.2DS 
is currently the strongest known risk factor for psycho-
sis and a promising model for studying the etiology of 
schizophrenia and early signs of psychosis proneness.5,6
As in individuals without 22q11.2DS, psychotic symp-
toms develop gradually in those with 22q11.2DS, and 
psychosis is usually preceded by subthreshold sympto-
mology.7,8 Few studies have assessed subthreshold psy-
chotic symptoms in 22q11.2DS reporting prevalence 
rates ranging from 20% to 56.5%.5,9–12 Small sample 
sizes, differences in participants’ age, various definition 
of “prodromal symptoms” used (ie, including positive 
symptoms, negative/disorganized symptoms, or both), 
and the assessment tool employed, may contribute to the 
variability in reported rates.
These inconsistencies call for additional investigation 
into the incidence and characteristics of subthreshold 
psychotic symptoms in 22q11.2DS from early childhood 
through adulthood. An analysis that is based on a large 
cohort of participants undergoing comparable clinical 
assessments is likely to provide answers to some of the 
questions that arise due to the limitations in the literature.
Several well-validated diagnostic tools are applied 
for assessing subthreshold psychotic symptoms, includ-
ing the Structured Interview for Prodromal Syndromes 
(SIPS).13 Originally developed for the evaluation of sub-
threshold psychotic symptoms in the general popula-
tion,14 the SIPS has good psychometric properties,13 and 
criteria for a clinical high-risk state have been shown to 
predict conversion to psychosis in populations without 
22q11.2DS (~20% by 1-year and 33% by 3-years).15,16 
The SIPS has been effectively administered to individuals 
with 22q11.2DS in several studies.5,9–12
Several factors may contribute to developing psycho-
sis in individuals with 22q11.2DS. Among these are lon-
gitudinal decline in verbal IQ (VIQ),17,18 lower baseline 
IQ,3,8,19 the presence of comorbid anxiety disorders,7,8,20 
and lower global functioning.21,22 However, the comor-
bidity of these conditions with subthreshold psychotic 
symptoms has not been sufficiently explored. Moreover, 
assessment of this phenomenon in 22q11.2DS individu-
als of various ages is vital for elucidating the rate and 
nature of subthreshold psychotic symptoms across devel-
opment in this population.
Accordingly, the aims of the current study are: (1) to 
determine the rates of positive and negative/disorganized 
subthreshold psychotic symptoms in the largest cohort of 
22q11.2DS individuals published to date; (2) to investigate 
(cross-sectional) changes in the prevalence of different 
definitions of subthreshold symptoms across develop-
ment—from early childhood throughout adulthood; (3) 
To determine whether higher rates of psychiatric comor-
bidities and lower intellectual and global functioning co-
occur with subthreshold psychotic symptoms.
Methods
Participants
This study represents the collaborative efforts of research-
ers across 10 independent medical centers worldwide, 6 in 
the United States, 3 in Europe, and 1 in Israel (table  1 
lists the demographics and enrollment specifications for 
each site). The sites are part of the International 22q11.2 
Deletion Syndrome Brain Behavior Consortium (IBBC). 
Participants had a 22q11.2 microdeletion confirmed by 
molecular testing, underwent a structured clinical assess-
ment of psychiatric psychopathologies, and completed 
the SIPS interview for evaluating subthreshold psychotic 
symptoms. Of the 839 individuals originally enrolled in 
the study, 79 were excluded due to missing data on the 
SIPS positive symptoms (>9%), resulting a total of 760 
participants aged 6–55 years (mean age = 17.1 ± 6.8).
Of the study sample (n = 760), 56 participants (7.4%) 
were on antipsychotic medication, 118 participants (15.5%) 
were taking antidepressants, 26 participants (3.4%) were 
taking a mood-stabilizer, 34 participants (4.5%) were tak-
ing an anxiolytic medication and 104 participants (13.7%) 
were taking stimulants.
Each site received approval from its local ethics com-
mittee (institutional review board; IRB), and each partic-
ipant or his or her legal caregiver gave written informed 
consent prior to study entry.
SIPS Administration and Scoring
Participants were evaluated for the presence of subthresh-
old psychotic symptoms by a well-trained Bachelor’s, 
Master’s, Doctoral, or Post-doctoral/Resident-level inter-
viewers skilled in using the SIPS Scale of Prodromal 
Symptoms (SOPS).13 Furthermore, all interviewers were 
routinely supervised by psychiatry and psychology fac-
ulty, knowledgeable in using the SIPS, at each of the 
participating sites.
The SOPS is composed of 19 items, each representing 
a different possible subthreshold psychotic symptom, 
yielding 4 constructs: positive, negative, disorganized, 
and general symptoms.13 Each item is rated on a 7-point 
scale (0—absent, 1—questionably present, 2—mild, 3—
moderate, 4—moderately severe, 5—severe but not psy-
chotic, 6—severe and psychotic/extreme).
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Some items of the SIPS are more entangled with non-
psychotic comorbidities. For example, D3, “trouble with 
focus and attention,” overlaps significantly with ADHD, 
and N5, poor “ideational richness,” overlaps with 
reduced intellectual ability. In these cases, we considered 
that these symptoms nevertheless might represent sub-
threshold psychotic symptoms. Therefore, we rated these 
SIPS items based on their presence and without regard to 
other comorbidities. As such, dual scoring was given for 
the same symptom of inattention in the SIPS and in the 
ADHD section of the K-SADS. This is consistent with 
the original intention of the SIPS, that items be rated 
without regard to diagnostic etiology.23
In the majority of cases, separate interviews were con-
ducted with probands and their caregivers, usually moth-
ers. The SIPS was administered separately from the child 
to all parents of children younger than 18 years of age, 
as well as for parents of adult participants when possible. 
Younger probands (aged 6–10  years) underwent clini-
cal evaluations probing for subjective and characteristic 
symptoms (including delusional and bizarre ideas, suspi-
ciousness, grandiosity, perceptual abnormalities, disorga-
nized speech, social anhedonia, and avolition). Probands 
aged 11 years and older received the full SIPS. Whenever 
there were discrepancies in the provided information, 
each responder was asked for clarification.
Establishing Reliability in Assessing Subthreshold 
Psychotic Symptoms Between Two Participating Sites: 
Philadelphia and Israel
The Tel Aviv and Philadelphia sites are funded, as part 
of a binational prospective research project, to study psy-
chosis risk in 22q11.2DS. Thus, the 2 centers conducted 
training sessions to ensure the consistency of SIPS 
administration and scoring methodology. The high inter-
rater reliability achieved suggests that multisite studies 
that aim to reliably assess subthreshold psychotic symp-
toms in individuals with 22q11.2DS are feasible. This is 
especially important in the context of administering the 
SIPS—which was originally developed for use in the gen-
eral population—to individuals with neurodevelopmental 
and neurogenetic conditions, such as 22q11.2DS. The low 
IQ (and, respectively, the poor ideational richness) that 
characterizes many 22q11.2DS individuals makes SIPS 
administration a challenging task that requires skilled 
personnel. The international 22q11.2 Deletion Syndrome 
consortium is a multicenter study geared toward char-
acterization of a large cohort of existing data sets. The 
retrospective nature of the project therefore focused on 
data harmonization and reliability is currently pursued in 
several sites. The following paragraph details the efforts 
of 2 sites.
The Israeli team was trained by the PI from the 
Philadelphia site (R.E.G) to administer the SIPS in the 
same manner that it is being conducted in the Philadelphia 
22q11.2DS study. Consequently, in both sites the SIPS 
interview was conducted separately for participants and 
caregivers. Whenever discrepancies emerged between the 
22q11.2DS and collateral informants, a combined rating 
was given in a consensus meeting. Four cases from the 
Israeli cohort were independently evaluated and given 
SIPS scores by R.E.G. and the clinical psychologist from 
the Israeli site (Y.G.).
The between-site weighted kappa intraclass correlation 
coefficients (ICC) for the SIPS items presented for both 
centers in this study ranged between very good to excel-
lent (besides the ICC for N5, “ideational richness”): P1, 
“unusual thought content/delusional ideas” (ICC = 0.99); 
P2, “suspiciousness/persecutory ideas” (0.98); P3, “gran-
diosity” (0.98); P4, “perceptual abnormalities/hallucina-
tions” (1.00); P5, “disorganized communication” (0.98); 
N1, “social anhedonia” (0.95); N2, “avolition” (0.95); 
N3, “expression of emotion” (0.98); N4, “experience 
of emotions and self” (1.00); N5, “ideational richness” 
(0.00); N6, “occupational functioning” (1.00); D1, “odd 
behavior or appearance” (0.97); D2, “dysphoric mood” 
(1.00); D3, “trouble with focus and attention” (0.89); and 
D4, “personal hygiene” (0.95).
Subthreshold Psychotic Symptoms Definitions
The spectrum of  subthreshold psychotic symptoms, 
consistent with the literature, was defined in 4 catego-
ries.5,16,24 Positive subthreshold psychotic symptoms—
having one or more positive symptoms rated 3–5; acute 
positive subthreshold psychotic symptoms—having at 
least one positive symptom rated 6 without fulfilling 
criteria for a psychotic spectrum disorder; negative/
disorganized subthreshold psychotic symptoms—hav-
ing at least 2 negative/disorganized symptoms rated 3–6 
(without the presence of  positive subthreshold symp-
toms); positive and negative/disorganized subthresh-
old psychotic symptoms—having one or more positive 
symptoms rated 3–5 and at least 2 negative/disorganized 
symptoms rated 3–6.
Psychiatric Evaluation
Probands and their caregivers were interviewed by 
trained psychiatrists or psychologists using the Schedule 
for Affective Disorders and Schizophrenia for School-
Aged Children, Present and Lifetime (K-SADS-PL)25 
in 8 centers, the Diagnostic Interview for Children and 
Adolescents (DICA)26 in one center (Geneva), and the 
Child and Adolescent Psychiatric Assessment (CAPA)27 
in another center (Cardiff). Adult participants were inter-
viewed using the Structured Clinical Interview for Axis 
I DSM-IV (SCID)28 in 9 centers and the PAS-ADD clini-
cal interview for adults29 in one center (Cardiff).
Psychiatric diagnoses were established, when appro-
priate, according to the fourth edition of the Diagnostic 
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and Statistical Manual of Mental Disorders (DSM-IV).30 
Nearly all of the participants underwent clinical evalu-
ation for the presence of schizophrenia spectrum disor-
ders (n = 756; 64 fulfilled the criteria), anxiety disorders 
(n  =  757; 310 fulfilled the criteria), mood disorders 
(n = 760; 133 fulfilled the criteria), attention deficit/hyper-
activity disorders (ADHD; n = 732; 257 fulfilled the crite-
ria), oppositional defiant and conduct disorders (n = 731; 
26 fulfilled the criteria), and substance-related disorders 
(n = 626; 15 fulfilled the criteria). Prevalence rates of psy-
chotic disorders and other psychiatric comorbidities are 
detailed in supplementary table S1.
Of the 760 participants with complete data on the SIPS 
positive items, 68 were excluded from the statistical analysis 
due to fulfillment of the criteria for schizophrenia spectrum 
disorders (n = 64), or not completing clinical evaluation 
(n = 4). Consequently, the final study cohort included 692 
participants aged 6–55 years (mean age = 16.9 ± 6.7). Of 
them, 350 participants were males (50.6%), 429 Caucasians 
(62%), 235 Afro-Americans (34%), 10 of mixed ethnicity 
(1.4%), and 9 Hispanic (1.3%).
Intellectual Functioning
Age-appropriate Wechsler intelligence scales were used 
for assessment of intellectual functioning, including the 
Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI),31 the Wechsler Intelligence Scale for Children-
Revised (WISC-R),32 the Wechsler Intelligence Scale 
for Children-Third Edition (WISC-III),33 the Wechsler 
Abbreviated Scale of Intelligence-Second Edition 
(WASI-II),34 and the Wechsler Adult Intelligence Scale-
Third Edition (WAIS-III).35 A total of 521 participants 
(68.4%) completed the evaluation. The mean full-scale 
IQ (FSIQ) was 76.3  ±  13.2 points, and the mean VIQ 
(assessed in 507 participants) was 79.8  ±  13.7 points. 
There were 187 individuals (35.9%) with a FSIQ ≤70, 
consistent with intellectual disability. Age was not sig-
nificantly associated with FSIQ score (Pearson r =  .03, 
P = .45).
Statistical Analysis
Statistical analysis was conducted using SPSS Version 
20.0. To compare the rates of subthreshold psychotic 
symptoms at different stages of development, the cohort 
was divided into 4 age groups: 6–12  years (children), 
13–17  years (adolescents), 18–25  years (young adults), 
and 26  years and above (older adults). The prevalence 
rates of positive subthreshold psychotic symptoms (ie, 
having one or more positive symptoms rated 3–5) and 
the combined subgroup of symptoms (ie, having one or 
more positive symptoms rated 3–5 and/or at least 2 nega-
tive/disorganized symptoms rated 3–6) were compared 
between the four different age groups using the χ2 test and 
with Fisher exact test when the χ2 test assumptions were 
not met. A significant difference between all 4 groups was 
followed by post hoc contrast analysis comparing the 
group with the highest rates of subthreshold symptoms 
(Adolescents, aged 13–17 years) to all other groups. The 
false discovery rate (FDR) method for adjustment of 
significance level was computed using SAS for Windows 
version 9.4.
Univariate analysis of variance (ANOVA) was applied 
to examine differences in the scores of individual SIPS 
items between the age groups. Bonferroni post hoc com-
parisons were conducted only for the items that reached 
statistical significance at the level of P < .003 (0.05/15, 
with 15 representing the number of comparisons/number 
of SIPS items).
Next, independent t-tests were calculated to compare 
between (a) 22q11.2DS with positive subthreshold psy-
chotic symptoms (ie, having one or more positive symp-
toms rated 3–5) vs those without positive subthreshold 
symptoms or acute positive subthreshold symptoms, and 
(b) 22q11.2DS with negative/disorganized subthreshold 
psychotic symptoms (ie, having at least 2 negative/disor-
ganized symptoms rated 3–6) vs those without positive or 
negative/disorganized subthreshold symptoms. Analyses 
were corrected for multiple comparisons (P value lower 
than .0062 was regarded as significant). The positive 
and negative/disorganized subthreshold symptoms were 
chosen as each of them is a risk factor for the evolution 
of psychotic disorders in individuals with- and without-
22q11.2DS. Potential contribution of research sites to the 
variability in individual items between the age groups was 
controlled for by including site as covariate (supplemen-
tary table S3).
Results
Prevalence of Subthreshold Psychotic Symptoms
Nearly one-third of participants met criteria for posi-
tive subthreshold psychotic symptoms (228/692; 32.8%), 
less than 1% qualified for acute positive subthreshold 
psychotic symptoms (6/692), and almost a quarter of 
participants met criteria for negative/disorganized sub-
threshold psychotic symptoms where positive subthresh-
old psychotic symptoms were not present (140/641; 
21.7%). Finally, one-fourth of participants (160/692; 
25.6%) met criteria for both positive and negative/disor-
ganized subthreshold psychotic symptoms.
About 90% of the participants who rated 6 on at least 
one positive SIPS item were diagnosed with a psychotic 
disorder (48/54) compared to 6% of those who rated 3–5 
(15/242), χ2(1) = 180.18, P < .001, η2 =.78. Participants 
with both positive and negative/disorganized symptoms 
were more likely to be diagnosed with psychotic disorder 
(7/167) compared to participants who met criteria for the 
negative/disorganized definition solely (0/140), Fisher’s 
exact test = 6.00, df = 1, P < .05.
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Notably, 66.3% of the participants did not meet cri-
teria for either positive or acute positive subthreshold 
psychotic symptoms (459/692). Of this group, the major-
ity (65.9%) did not meet criteria for the negative/disorga-
nized definition either.
The most prevalent subthreshold symptom was poor 
ideational richness, followed by trouble with focus and 
attention, avolition, and occupational functioning. The 
least prevalent symptoms were grandiosity and bizarre 
thinking. Individual item scores and subthreshold rates 
in the entire 22q11.2DS cohort are described in table 2.
Subthreshold Psychotic Symptoms From Early 
Childhood Throughout Adulthood
Significant differences between the age groups were found 
in the positive subthreshold psychotic symptoms sub-
group and the combined (positive and negative/disorga-
nized) subthreshold psychotic symptoms subgroup. Post 
hoc contrast analysis using FDR for adjustment of sig-
nificance level revealed significantly higher rates of posi-
tive subthreshold symptoms in adolescents compared to 
children, FDR = 0.039, χ2(1) = 6.07, P < .02, η2 =  .12, 
and older adults, FDR  =  0.047, χ2(1)  =  4.47, P < .03, 
η2 =  .12. In the same vein, a post hoc contrast analysis 
conducted for the combined subthreshold symptoms 
subgroup revealed higher rates in adolescence compared 
to children, FDR = 0.027, χ2(1) = 9.30, P < .003, η2 = .18, 
and older adults, FDR = 0.013, χ2(1) = 8.34, P < .005, 
η2 = .20. The acute positive symptom subgroup has been 
diagnosed in a limited number of individuals, and it was 
present in children and adolescents but absent among 
adults (table 3).
Age-related differences in mean scores of positive, neg-
ative, and disorganized symptoms emerged. Specifically, 
adolescents scored higher on items: P4, “perceptual 
abnormalities/hallucinations,” F(3, 686) = 6.20, P < .001, 
η2  =  .02; N1, “social anhedonia,” F(3, 616)  =  6.94, 
P < .001, η2  =  .03; N3, “expression of emotion,” F(3, 
617)  =  17.00, P  <  .001, η2  =  .07, N4, “experience of 
emotions and self”, F(3, 597) = 6.11, P < .001, η2 = .03, 
and, N5, poor “ideational richness”, F(3, 617) = 17.33, 
P  <  .001, η2  =  .08, compared to all or most other age 
groups. Finally, children and adolescents scored signifi-
cantly higher on item D3, “trouble with focus and atten-
tion”, F(3, 620) = 16.92, P < .001, η2 = .08, compared to 
the young adults and older adults groups (see figure 1 and 
supplementary table S2 for details).
Psychiatric Comorbidities, Intellectual Functioning, 
and Global Functioning in Affected Vs Nonaffected 
Individuals
The rates of anxiety disorders has been significantly higher 
in participants with positive subthreshold psychotic 
symptoms compared to those without (55.1% vs 35.1%, 
χ2(1) = 25.54, P < .001, η2 = .19; table 4). In addition, intel-
lectual functioning (FSIQ) and global functioning (GAF) 
scores were lower in subjects with positive subthreshold 
symptoms compared to those without (FSIQ, 74.4 ± 12.0 
vs 78.2 ± 13.3, t(467) = 3.01, P = .002; GAF, 57.4 ± 12.1 
vs 69.4 ± 46.6, t(664) = 3.83, P < .001) (table 4).
The rates of anxiety disorders and ADHD have been 
significantly higher in subjects with negative/disorganized 
subthreshold psychotic symptoms compared to those 
without (43.6% vs 29.6%, χ2(1) = 7.94, P = .006, η2 = .14, 
and 44.0% vs 27.3%, χ2(1) = 10.75, P =  .001, η2 =  .16, 
respectively; table  4). Intellectual functioning (FSIQ, 
VIQ) and global functioning (GAF) scores have been 
lower in subjects with negative/disorganized subthreshold 
symptoms compared to those without (FSIQ, 75.8 ± 12.3 
vs 80.7 ± 12.8, t(268) = 3.12, P = .002; VIQ, 78.3 ± 12.7 vs 
83.3 ± 13.7, t(258) = 1.77, P = .004; GAF, 60.4 ± 14.8 vs 
71.4 ± 11.35, t(384) = 8.13, P < .001, respectively).
Table 2. Individual SIPS Item Scoring and Subthreshold Rates of 22q11.2 Deletion Syndrome Participants Without Psychotic Disorder
Item Description Mean ± SD Median Range Subthreshold, %a
P1 Unusual thought content/delusional ideas 0.96 ± 1.29 0 0–6 13.4
P2 Suspiciousness/persecutory ideas 0.93 ± 1.21 0 0–6 13.7
P3 Grandiosity 0.38 ± 0.87 0 0–6 4.5
P4 Perceptual abnormalities/hallucinations 1.11 ± 1.47 0 0–6 18.8
P5 Disorganized communication 0.85 ± 1.15 0 0–5 10.1
N1 Social anhedonia 1.49 ± 1.51 1 0–6 21.9
N2 Avolition 1.59 ± 1.51 1 0–6 31.0
N3 Expression of emotion 1.14 ± 1.38 1 0–6 19.1
N4 Experience of emotions and self 0.59 ± 1.08 1 0–5 7.5
N5 Ideational richness 2.31 ± 1.65 2 0–6 48.5
N6 Occupational functioning 1.45 ± 1.51 1 0–6 23.4
D1 Odd behavior or appearance 0.62 ± 1.04 0 0–5 7.9
D2 Bizarre thinking 0.40 ± 0.84 0 0–5 3.8
D3 Trouble with focus and attention 2.00 ± 1.44 2 0–5 39.9
D4 Personal hygiene 0.76 ± 1.18 0 0–5 10.8
aSubthreshold level was defined as a score of 3–6 in any given item.
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Discussion
This multisite study represents the largest cohort and 
the most comprehensive analysis reported to date on 
subthreshold psychotic symptoms in individuals with 
22q11.2DS. The novel aspects of  our study include an 
examination of  the development of  subthreshold psy-
chotic symptoms by age groups, and evidence that cogni-
tive deficits are associated with subthreshold psychosis 
in this population. Specifically, we show that the peak 
prevalence of  positive subthreshold psychotic symptoms 
occurs during adolescence and young adulthood (aged 
13–25 years), which is similar or slightly later than the 
peak occurrence of  subthreshold syndrome reported 
in non-help-seeking typically developing individuals.36 
Furthermore, our findings indicate that FSIQ scores 
are significantly lower in 22q11.2DS individuals with 
vs without subthreshold psychotic symptoms. Of note, 
lower IQ has been associated with psychotic disorders2 
and with the risk for developing psychotic disorders in 
22q11.2DS.7
Psychiatric comorbidities in 22q11.2DS are common,2 
and our study provides additional evidence that condi-
tions of subthreshold psychosis are characterized by an 
extent of psychiatric symptomology, including anxiety 
and mood disorders and higher rates of ADHD,37 coupled 
with lower FSIQ scores. These comorbidities are similar 
to those reported in individuals without 22q11.2DS.38,39 
Findings in individuals without 22q11.2DS show that 
psychiatric disorders tend to be less specific in early stages 
and more so with progression.39 Notably, the majority of 
individuals without 22q11.2DS showing subthreshold 
psychotic symptoms do not develop schizophrenia spec-
trum disorders.40 Many patients with subthreshold psy-
chotic symptoms progress to develop other psychiatric 
disorders such as anxiety and affective disorders.
Table 3. Subthreshold Psychotic Symptoms Across the Life Span in 22q11.2 Deletion Syndrome Participants Without Psychotic 
Disorder
Definitions
No. (%)a
Children 
(n = 184)
Adolescents 
(n = 276)
Young Adults 
(n = 231)
Older Adults  
(n = 67) χ2 P ES
Positive subthreshold symptoms 48/175 (27.4) 97/251 (38.5) 69/203 (33.9) 13/55 (23.6) 8.31 .04 .11
Negative/disorganized subthreshold 
symptoms
34/126 (27.0) 55/142 (38.7) 40/143 (28.0) 11/47 (23.4) 6.81 .08 .12
Positive + negative/disorganized 
subthreshold symptoms
31/123 (25.2) 69/156 (44.2) 52/155 (33.5) 8/44 (18.2) 16.50 <.001 .19
Acute positive subthreshold symptoms 1/175 (<0.5) 5/159 (3.1) 0/134 (0) 0/42 (0) 6.82 .08 .12
Note: ES, effect size Eta-squared (η2).
a% of valid cases (participants for whom the SIPS negative/disorganized symptoms were missing were withdrawn from the relevant 
analysis; n = 67); Statistical analysis conducted with chi-square tests (χ2); Children, aged 6–12 years, mean age 10.3 ± 1.4; Adolescents, 
13–17 years, 14.9 ± 1.4; Young adults, 18–25 years, 20.7 ± 2.2; Older adults, 26 years and above, mean age 33.0 ± 6.5; Male/female ratio 
did not differ between the 4 age groups, χ2(3) = 4.94, P = .18.
Fig. 1. Comparison of the mean scores of individual SIPS items between the four 22q11.2 deletion syndrome age groups; mean + SEM; 
**P < .01; ***P < .001.
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It is plausible that the subthreshold psychotic symp-
toms in 22q11.2DS are not pathognomonic since only 
a portion of  the individuals with 22q11.2DS develop 
psychosis while many others will evolve to other psychi-
atric morbidities such as anxiety disorders and depres-
sion. An answer to this question will be provided by 
longitudinal studies that have only begun to examine 
the outcome of  22q11.2DS individuals with subthresh-
old psychotic symptoms.41 Besides the need to find the 
proportion of  subthreshold 22q11.2DS individuals 
who will develop full-blown psychosis, it is also impor-
tant to determine the proportion of  the subthreshold 
22q11.2DS individuals who will continue to cope with 
or will develop mood disorders, anxiety disorders and 
ADHD,37 as these disorders have been shown to nega-
tively affect the quality of  life and functioning of  indi-
viduals with 22q11.2DS.42–44
The collective prevalence rates of those with positive 
subthreshold symptoms (32.8%) and those with negative/
disorganized subthreshold symptoms (21.7%) sum up to 
54.5%, which is similar to the 54% who met criteria for 
“psychosis-proneness” in the research conducted by Tang 
et  al.5 Similarly, the rates of negative/disorganized sub-
threshold symptoms found in our cohort parallel those 
reported in several previous studies with 22q11.2DS 
individuals, suggesting that negative symptoms are com-
mon in this population.11,22
Negative symptoms are considered important predic-
tors of the likelihood to convert to psychosis in high-risk 
populations without 22q11.2DS.11,45 For example, mod-
erate and severe subthreshold negative symptoms were 
highly abundant in individuals at high risk for psychosis 
in the North American Prodrome Longitudinal Study 
(NAPLS), and the severity and persistence of these symp-
toms were positively associated with transition rates into 
a psychotic state at 6- and 12-months post-baseline vis-
its.45 Another study which assessed negative subthreshold 
psychotic symptoms in typically developing youths found 
significant associations with the participants’ neurocog-
nitive performance and functions that are central to the 
evolution of psychosis.46 Taken together, the accumulat-
ing evidence suggest that 22q11.2DS individuals with sub-
threshold negative symptoms in our study are at higher 
risk of transitioning into full-blown psychotic disorders.
Nevertheless, in 22q11.2DS literature, negative symp-
toms, most notably, ideational richness and trouble with 
focus and attention (ie, ADHD), have been suggested 
as features of the general phenotype of the syndrome,47 
regardless of the degree of the risk for psychosis. This 
indicates that negative symptoms may not yield the 
Table 4. Comparing Rates of Psychiatric Comorbidities and Level of Intellectual and Global Functioning in 22q11.2 Deletion 
Syndrome Participants With Subthreshold Psychotic Symptoms Vs Those Without
Variables
No. (%)a
Positive Subthreshold  
Psychotic Symptoms
Non-Subthreshold 
Psychotic Symptoms t/χ2 P ES
Any anxiety disorder 125/227 (55.1) 161/459 (35.1) 25.54 <.001 .19
Any mood disorder 45/227 (19.8) 65/459 (14.2) 3.66 .06 .07
Any ADHD 89/218 (40.8) 153/447 (34.2) 2.75 .10 .06
Any disruptive disorder 7/218 (3.1) 15/447 (3.3) .01 .92 .001
Substance-related disorder 5/188 (2.6) 7/375 (1.9) .38 .54 .02
FSIQ, mean ± SD 74.4 ± 12.1 78.2 ± 13.3 3.16 <.01 .30
VIQ, mean ± SD 78.8 ± 12.7 81.2 ± 13.7 1.86 .06 .18
GAF, mean ± SD 57.4 ± 12.1 69.4 ± 46.6 3.83 <.001 .35
Negative/disorganized 
Subthreshold Symptoms
Non-Subthreshold 
Symptoms t/χ2 P ES
Any anxiety disorder 61/140 (43.6) 80/270 (29.6) 7.64 <.01 .14
Any mood disorder 26/140 (18.6) 35/270 (12.9) 2.29 .13 .07
Any ADHD 59/134 (44.0) 73/264 (27.3) 10.75 <.001  16
Any disruptive disorder 4/134 (2.9) 6/264 (2.3) .18 .67 .02
Substance-related disorder 3/119 (2.5) 4/255 (1.5) .41 .52 .03
FSIQ, mean ± SD 75.8 ± 12.3 80.7 ± 12.8 3.13 <.01 .39
VIQ, mean ± SD 78.3 ± 12.7 83.3 ± 13.7 2.92 <.01 .38
GAF, mean ± SD 60.4 ± 14.8 71.4 ± 11.3 7.63  <.001 .84
Note: ADHD, attention deficit hyperactivity disorder; FSIQ, full-scale IQ; VIQ, verbal IQ; GAF, global assessment of functioning; ES, 
effect size (Eta-squared [η2] for chi-square; Cohen’s d for t-test).
a% of valid cases (excluding those with missing data); Statistical analysis was conducted with Chi-square tests (χ2) in case of rates 
comparison, and with independent t-test in case of means comparison; Two categories are tabulated: positive subthreshold and then 
separately the negative/disorganized subthreshold symptoms.
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predictive power that positive symptoms may yield, par-
ticularly in adolescents who are more likely to endorse 
negative symptoms than children and, in some cases, 
adults.48 Accordingly, future studies should examine 
whether, and at what ages, the presence of negative 
subthreshold symptoms also predicts the emergence of 
psychosis in the 22q11.2DS population. Prospective mul-
ticenter studies are needed to adapt the SIPS to neurode-
velopmental disorders with below-average IQ and excess 
psychiatric comorbidities (including ADHD), as is the 
case with most individuals with 22q11.2DS.
A limitation of the current analysis might be related to 
the lack of establishing cross-site reliability of the SIPS. 
However, the Tel Aviv and Philadelphia sites conducted 
joint training sessions to ensure the consistency of SIPS 
administration and scoring methodology (as detailed in 
the Methods section). The inter-rater reliability scores 
achieved were excellent (besides N5, kappa scores ≥ 0.89), 
indicating the feasibility of multisite studies that aim to 
reliably assess subthreshold psychotic symptoms in indi-
viduals with 22q11.2DS. The pilot inter-site reliability 
obtained in this study encourage conducting interna-
tional multisite training and reliability.
Another limitation may relate to the cross-sectional 
rather than longitudinal nature of the current study 
design. As such, it was not possible to identify predictive 
factors of symptom progression over time. The predic-
tive value of the SIPS in terms of the likelihood of those 
presenting with subthreshold symptoms to transition to 
psychosis constitutes an important topic with marked 
clinical implications, and studies that examine this ques-
tion are currently underway.
Moreover, there was no information on the age at onset 
or worsening of subthreshold psychotic symptoms in the 
current cohort, which undermines the ability to deter-
mine whether those with subthreshold symptoms qualify 
for clinical high risk or ultra-high risk status. In addition, 
since we used dual scoring for subthreshold psychotic 
symptoms measured by the SIPS and for psychiatric 
symptoms measured by the K-SADS the reported rates 
of negative/disorganized symptoms might have been 
inflated and the associations between subthreshold symp-
toms and higher rates of ADHD and lower FSIQ scores 
can therefore be biased. Nevertheless, at this early stage 
of applying the SIPS to individuals with a neurogenetic 
disorder, we ought to adhere to the standard procedures. 
Prospective studies will need to examine these issues when 
adapting the SIPS to neurodevelopmental disorders con-
sidering relevant characteristics. Additionally, while the 
feasibility and utility of applying the SIPS to individuals 
with 22q11.2DS at various stages of development were 
supported by this study, there is still a need to standardize 
the methodology of its administration and verify its reli-
ability in the context of 22q11.2DS subthreshold psycho-
sis before it can be recommended for widespread clinical 
implementation.
In conclusion, the present study indicates that nearly a 
third of 22q11.2DS individuals meet criteria for positive 
subthreshold psychotic symptoms and almost a quar-
ter meet criteria for negative/disorganized subthreshold 
symptoms, with adolescents and young adults showing 
the highest rates of subthreshold symptoms. We found 
that 22q11.2DS individuals with subthreshold psychotic 
disorders have high rates of anxiety disorders and ADHD 
lower IQ and more impaired functioning. Future longi-
tudinal studies would demonstrate the predictive value 
of 22q11.2DS subthreshold psychotic symptoms and its 
associated features in the context of the propensity to 
transition to psychosis.
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Supplementary data are available at Schizophrenia 
Bulletin online.
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